Weiss Ratings Reiterates Sell (D-) Rating for Quanterix (NASDAQ:QTRX)

Quanterix (NASDAQ:QTRX)‘s stock had its “sell (d-)” rating reiterated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Canaccord Genuity Group restated a “hold” rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Quanterix has a consensus rating of “Hold” and a consensus price target of $11.75.

Quanterix Trading Up 6.0%

Shares of QTRX stock opened at $6.00 on Wednesday. The stock has a 50 day simple moving average of $5.08 and a 200-day simple moving average of $5.51. The company has a market cap of $278.82 million, a price-to-earnings ratio of -3.30 and a beta of 1.07. Quanterix has a 12-month low of $4.05 and a 12-month high of $15.67.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06). The company had revenue of $24.48 million for the quarter, compared to analyst estimates of $29.73 million. Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%. Quanterix has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Quanterix will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of Quanterix

Several large investors have recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its stake in Quanterix by 14.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after purchasing an additional 521,639 shares during the last quarter. Easterly Investment Partners LLC grew its holdings in shares of Quanterix by 38.8% during the first quarter. Easterly Investment Partners LLC now owns 1,325,620 shares of the company’s stock valued at $8,630,000 after buying an additional 370,625 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Quanterix by 2.0% during the second quarter. William Blair Investment Management LLC now owns 1,127,981 shares of the company’s stock valued at $7,501,000 after purchasing an additional 21,918 shares in the last quarter. Blue Water Life Science Advisors LP raised its position in Quanterix by 157.3% in the second quarter. Blue Water Life Science Advisors LP now owns 957,747 shares of the company’s stock worth $6,369,000 after acquiring an additional 585,572 shares during the period. Finally, Invenomic Capital Management LP bought a new stake in Quanterix in the first quarter worth about $5,872,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.